Document Detail

Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine.
MedLine Citation:
PMID:  21256431     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Methamphetamine (MA) use among pregnant women is an increasing problem in the United States. The impact of prenatal MA exposure on development in childhood is unknown.
OBJECTIVE: To examine the effects of prenatal MA exposure on motor and cognitive development in children at 1, 2, and 3 years of age.
DESIGN/METHODS: IDEAL enrolled 412 mother-infant pairs at four sites (Tulsa OK, Des Moines IA, Los Angeles CA, and Honolulu HI). MA subjects (n=204) were identified by self report or GC/MS confirmation of amphetamine and metabolites in infant meconium. Comparison subjects (n=208) were matched (race, birth weight, maternal education, and type of insurance), denied amphetamine use, and had a negative meconium screen. Both groups included prenatal alcohol, tobacco and marijuana use, but excluded use of opiates, lysergic acid diethylamide, phencyclidine or cocaine only. The Peabody Developmental Motor Scales (PDMS-2) were administered to the infants at the 1 and 3 year visits. This analysis includes a subsample (n=350) of the IDEAL study with completed 1 and/or 3 year visits (n=330 and 281, respectively). At each annual visit we also conducted the Bayley Scales of Infant Development (BSID-II) as a general evaluation of mental and motor development. The BSID-II analysis includes a subsample (n=356) of the IDEAL study with completed 1, 2, and/or 3 year visits (n=331, 288, and 278 respectively). GLM analysis conducted on the PDMS-2 and BSID-II examined the effects of MA exposure and heavy MA exposure (≥3 days of use/week), with and without covariates. Longitudinal analyses were used to examine the effects of MA exposure on changes in motor and cognitive performance over time.
RESULTS: Heavy MA exposure was associated with significantly lower grasping scores than some and no use at 1 year (P=0.018). In longitudinal analysis, lower grasping scores associated with any MA exposure and heavy exposure persisted to 3 years. There were no effects of MA exposure, including heavy exposure, on the Bayley Mental Development Index (MDI) or Psychomotor Development Index (PDI) at any or across age.
CONCLUSIONS: There were no differences in cognition as assessed by the BSID-II between the groups. There was a subtle MA exposure effect on fine motor performance at 1 year with the poorest performance observed in the most heavily exposed children. By 3 years, no differences in fine motor performance were observed. These findings suggest MA exposure has modest motor effects at 1 year that are mostly resolved by 3 years.
Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; William Haning; Amelia Arria; Marilyn Huestis; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Hai Lin; Barry M Lester
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Neurotoxicology and teratology     Volume:  33     ISSN:  1872-9738     ISO Abbreviation:  Neurotoxicol Teratol     Publication Date:    2011 Jan-Feb
Date Detail:
Created Date:  2011-01-24     Completed Date:  2011-05-06     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  8709538     Medline TA:  Neurotoxicol Teratol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  176-84     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Child Behavior / drug effects,  psychology*
Child Development / drug effects*
Child, Preschool
Cognition / drug effects*
Cross-Sectional Studies
Infant Behavior / drug effects,  psychology
Infant, Newborn
Longitudinal Studies
Methamphetamine / toxicity*
Motor Activity / drug effects*
Prenatal Exposure Delayed Effects / chemically induced*,  physiopathology,  psychology
Social Class
Grant Support
3 M01 RR00425/RR/NCRR NIH HHS; P20 RR11091/RR/NCRR NIH HHS; R01 DA014948/DA/NIDA NIH HHS; R01 DA014948-01/DA/NIDA NIH HHS; R01 DA014948-02/DA/NIDA NIH HHS; R01 DA014948-03/DA/NIDA NIH HHS; R01 DA014948-03S1/DA/NIDA NIH HHS; R01 DA014948-04/DA/NIDA NIH HHS; R01 DA014948-05/DA/NIDA NIH HHS; R01 DA014948-06/DA/NIDA NIH HHS; R01 DA014948-07/DA/NIDA NIH HHS; R01 DA014948-08/DA/NIDA NIH HHS; R01 DA014948-09/DA/NIDA NIH HHS; R01 DA014948-10/DA/NIDA NIH HHS; R01 DA014948-11/DA/NIDA NIH HHS; R01DA014948/DA/NIDA NIH HHS; R01DA021757/DA/NIDA NIH HHS
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A new look at quantifying tobacco exposure during pregnancy using fuzzy clustering.
Next Document:  Sexual selection.